Dual Inhibition of PI3K and mTOR as an Alternative Treatment for Kaposi's Sarcoma

Risa Chaisuparat,1, Jiadi Hu,1 Bruno C. Jham,1 Zachary A. Knight,3 Kevan M. Shokat,1,2 and Silvia Montaner 1

1Department of Oncology and Diagnostic Sciences; 2Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland; and 3Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California

Abstract

Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal transplant rejection, has recently emerged as an effective treatment for Kaposi's sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis. Indeed, recent work supports a role for mTOR as a central player in the transformation of endothelial cells by the KS-associated herpesvirus–encoded G protein–coupled receptor (vGPCR), the viral oncogene believed to be responsible for causing KS. However, emerging evidence that rapamycin may transiently promote the activation of Akt may limit its use as an anti-KS therapy. Here, we show that activation of Akt in endothelial cells expressing vGPCR is augmented by treatment with rapamycin, resulting in the up-regulation of several Akt proliferative and survival pathways. However, use of a novel dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor, PI-103, effectively and independently blocked activation of both PI3K and mTOR in vGPCR-expressing endothelial cells. This resulted in more effective inhibition of endothelial cell proliferation and survival in vitro and tumor growth in vivo. Our results suggest that PI-103 may be an effective therapeutic option for the treatment of patients with KS. Moreover, as KS may serve as a model for pathologic angiogenesis, our results further provide the basis for the early assessment of PI-103 as an antiangiogenic chemotherapeutic. [Cancer Res 2008;68(20):8361–8]

Introduction

Kaposi's sarcoma (KS) is a multifocal vascular neoplasm that affects immunosuppressed individuals (1, 2). Indeed, as the most common acquired immune deficiency syndrome (AIDS)-related malignancy worldwide and the most frequent cancer among children and adult men in sub-Saharan Africa, KS has emerged as a major cause of morbidity and mortality among the AIDS population. Despite decades of investigation into the etiology of this enigmatic tumor, clinical management of KS has proven to be challenging.

Invariably associated with infection by the KS-associated herpesvirus (KSHV or HHV8), current research efforts have focused on the study of the relative contribution of KSHV-encoded genes to Kaposi's sarcomagenesis to identify novel mechanism-based therapies for patients suffering from this neoplasm. Although several viral genes bear potential for KS pathogenesis, compelling data point to the KSHV-encoded G protein–coupled receptor (vGPCR) as a leading candidate viral gene for the initiation of KS (3, 4). Expression of KSHV vGPCR in mice by endothelial cell–specific retroviral transduction (5) or in traditional transgenic models (6, 7) has revealed the remarkable sarcomagenic potential of this viral receptor.

Of interest, emerging evidence has implicated the Akt downstream effectors tuberous sclerosis complex (TSC)/mammalian target of rapamycin (mTOR) as a key intracellular route regulating endothelial cell biological responses, including endothelial tumor formation and pathologic angiogenesis (8–11). Indeed, we have recently shown that KSHV vGPCR activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway plays a fundamental role in KS development and that rapamycin (sirolimus) is able to block vGPCR oncogenesis in vitro and in vivo (12). Of interest, this drug is an efficient therapy for transplant recipients with (iatrogenic) KS (13, 14) as well as for patients with the classic form of the disease (15, 16). However, treatment with rapamycin has not been successful in all KS patients (17–20). Why this treatment is successful in some patients, but not in others, remains unclear; the recent observation that rapamycin causes transient up-regulation of Akt and Akt-mediated survival in some normal and tumor cells may provide one explanation (21–23). Indeed, as Akt activation is a recurring theme in oncogenesis, this transient up-regulation of Akt may expose a potential Achilles' heel of rapamycin as a chemotherapeutic agent (24, 25).

Of note, a novel chemotherapeutic drug, PI-103, has recently been shown to independently inhibit both PI3K and mTOR (26), thereby overcoming a potential disadvantage of rapamycin in the treatment of Akt-dependent tumors. We therefore set out to assess the efficacy of PI-103 for the treatment of KS. Our results show that PI-103 blocks endothelial cell proliferation and survival more efficiently than rapamycin and demonstrate the potential of inhibiting both PI3K and mTOR as an effective antiangiogenic approach.

Materials and Methods

Expression plasmids and reagents. The expression plasmids for KSHV vGPCR, vGPCR R143A, Rheb, and enhanced green fluorescent protein have been described elsewhere (11, 12). LY294002 and rapamycin were purchased from Calbiochem. The dual PI3K/mTOR inhibitor PI-103 has been previously described (26). For in vitro studies, rapamycin, LY294002, and PI-103 were reconstituted in DMSO as 1000× stock solutions and were further diluted to the working concentration in culture medium. For in vivo studies, rapamycin (LC Laboratories) was dissolved in 100% ethanol as 20 mg/mL stock solutions and further diluted in an aqueous solution of 5.2% Tween 80 and 5.2% polyethylene glycol immediately before use (27). PI-103 was dissolved in 100% DMSO (5 mg/mL) and subsequently diluted to 50% DMSO in water before use.
Cell lines and transfections and cell proliferation assays. Immortalized murine endothelial cells (SVEC), EC-vGPCR, EC-R143A, and COS-7 cells were cultured as previously described (5). Transfection of COS-7 was performed using PolyFect (Qiagen) according to the manufacturer's protocol. Cell proliferation was determined using the crystal violet staining assay (28).

5-Bromo-2-deoxyuridine uptake and flow cytometry. 5-Bromo-2-deoxyuridine (BrdUrd) uptake was determined using the BrdUrd Kit 1 from Roche Applied Sciences. Briefly, cells were plated on coverslips and serum starved for 24 h. BrdUrd (10 mmol/L) was added and cells were then treated with LY294002, rapamycin, or PI-103 for 6 h. Cells were fixed with ethanol fixative (50 mmol/L glycine solution into ethanol) and incubated with anti-BrdUrd working solution and anti-mouse Ig-fluorescein working solution. Cells were finally covered with Vectashield mounting medium containing propidium iodide (Vector Laboratories, Inc.). The samples were analyzed under a fluorescence microscope with a detection range of 515 to 565 nm. For apoptosis detection, 0.5 µL of Annexin V-FITC (BD Biosciences) and PI working solution were added to cells. Samples were analyzed by flow cytometry using the Annexin V-FTTC Apoptosis Detection kit (BD Biosciences) and propidium iodide staining.

Establishment and treatment of tumor allografts in athymic nu/nu mice. SVEC, EC-vGPCR, or EC-R143A (10^6) cells were used to induce allografts in 8-wk-old athymic (nu/nu) nude female mice as described (11). Briefly, early-passage, exponentially growing cells were harvested after stable selection with G418, washed with PBS, and resuspended in DMEM. Viable cells (10^6) were then transplanted s.c. in the right flank of the mouse. The animals were monitored thrice weekly for tumor formation. The longest length (L) and shortest width (W) of the tumor were measured using a caliper at different time points throughout the experiment. Tumor volume was then converted into tumor weight using the formula L/2W^2/2, as described previously (29). PI-103 treatment was commenced when estimated tumor weight reached ~0.25 g. For this procedure, tumor-bearing animals were randomly grouped (control, n = 5; PI-103–treated group, n = 5) and treated with PI-103 (10 mg/kg/d) or an equal volume of vehicle. Treatment schedule was a single injection per animal given i.p. for 18 consecutive days (26). Results of animal experiments were expressed as mean estimated tumor weight ± SD. When appropriate, animals were euthanized, and tissue was fixed in 4% paraformaldehyde and embedded in paraffin or lyzed for further analysis. For BrdUrd studies, mice were first given an i.p. injection of BrdUrd (100 mg/kg) 2 h before sacrifice. Detection of apoptotic cells was performed by terminal deoxynucleotidyl transferase (TdT)–mediated dUTP nick end labeling (TUNEL) assay using TdT end labeling with DIG. All procedures involving animals were approved by the Institutional Animal Care and Use Committee.

Western blots and immunohistochemistry. Western blots and immunohistochemical analysis were performed as previously described (5, 11). Antibodies recognizing phosphorylated Akt (P-Akt), Akt, phosphorylated S6 ribosomal protein (P-S6), S6 ribosomal protein, phosphorylated p38 (P-p38), p38, phosphorylated glycogen synthase kinase 3 (P-GSK3), GSK3, phosphorylated BAD (P-BAD), BAD, phosphorylated Mdm2 (P-Mdm2), p27, phosphorylated p70 S6K (P-S6K), and p70 S6K were obtained from Cell Signaling. Antibodies recognizing phosphorylated Akt, S6, p38, p70 S6K, or Mdm2 were obtained from R&D Systems and BD Biosciences, respectively.

Results

Rapamycin inhibits mTOR but up-regulates Akt signaling in vGPCR-expressing endothelial cells. KSHV, the human herpesvirus that causes KS, encodes a G protein–coupled receptor (vGPCR) that has been shown to reproduce KS-like tumors when expressed in transgenic mice (5–7). vGPCR is a homologue of the human chemokine receptors CXCR1 and CXCR2 that exhibits constitutive signaling to several oncogenic pathways (4, 30, 31).

Figure 1. Rapamycin up-regulates Akt signaling in KSHV vGPCR-expressing endothelial cells. A, tumor allografts were established in athymic nu/nu mice by injecting immortalized murine endothelial cells (SVECs) or SVECs expressing vGPCR (EC-vGPCR) or the inactive mutant vGPCR R143A (EC-R143A). Columns, mean estimated tumor weight (g); bars, SD. Data are from a representative independent experiment that was repeated twice with similar results. Western blot analysis shows the correlation with P-Akt, Akt, P-S6, or S6 expression levels. B, immunodetection of the levels of P-Akt, Akt, P-S6, P-p38, or p38 of EC-vGPCR cells treated with increasing doses of rapamycin (Rap), LY294002 (LY), or DMSO (Control) for 6 h. C, phosphorylation of Akt or Akt downstream molecules (GSK3, BAD, Mdm2, p27, p70 S6K, or S6) in EC-vGPCR cells treated with 10 nmol/L rapamycin, 10 µmol/L LY294002, or DMSO (Control) for 6 h.
Immortalized murine vascular endothelial cells (SVECs) expressing vGPCR (EC-vGPCR) are highly tumorigenic in nude mice (Fig. 1A, top). A single point mutation in the highly conserved DRY sequence abrogates vGPCR constitutive activity (32); in turn, murine endothelial cells stably expressing this inactive vGPCR R143A mutant (EC-R143A) are not tumorigenic. Of interest, the oncogenic potential of vGPCR seems to correlate with its ability to signal to Akt and its effector kinase, mTOR (Fig. 1A, bottom). These results suggest that constitutive signaling to Akt and mTOR may play a fundamental role in vGPCR oncogenesis.

Of note, several studies have shown the efficacy of the mTOR inhibitor, rapamycin (sirolimus), in the treatment of transplant recipients with (iatrogenic) KS (13, 14) as well as patients with classic KS (15, 16). However, recent reports documenting the therapeutic failure of rapamycin for some KS patients suggest that the relationship among vGPCR, mTOR, and rapamycin in KSHV-infected endothelial cells may be more complicated than previously thought (17–20). Indeed, emerging evidence points to a complex regulation of Akt/TSC/mTOR activity (24, 25). An intriguing recent finding is that Akt is up-regulated in some cells treated with rapamycin as a result of the loss of mTOR-mediated inhibitory feedback mechanisms (21–23, 25). We therefore set out to determine whether Akt was up-regulated in vGPCR-expressing endothelial cells on treatment with rapamycin. As shown in Fig. 1B, treatment of EC-vGPCR cells with increasing doses of rapamycin for 6 h resulted in an inhibition of mTOR; however, the levels of phosphorylated Akt increased in a dose-dependent manner. Conversely, EC-vGPCR cells exposed to increasing doses of the PI3K inhibitor LY294002 showed inhibition of both Akt and mTOR under the same experimental conditions.

We then investigated whether the increase in the phosphorylation of Akt observed in EC-vGPCR cells treated with rapamycin was associated with an increased phosphorylation of endogenous Akt substrates. We found that treatment of vGPCR-expressing endothelial cells with rapamycin resulted in a marked increase in the phosphorylation of GSK3 and BAD (Fig. 1C). Phosphorylation of other Akt downstream effectors was unaffected (MDM2 and p27) or down-regulated (p70 S6K and S6 ribosomal protein). Collectively, these results suggest that, while inhibiting vGPCR-induced mTOR activity, rapamycin treatment may simultaneously lead to functional activation of Akt signaling in vGPCR-expressing endothelial cells.

Treatment of vGPCR-expressing endothelial cells with PI-103 inhibits activation of both Akt and mTOR independently. These findings suggest that inhibiting Akt activation in rapamycin-treated KS tumors may improve the efficacy of rapamycin treatment for vGPCR-induced tumorigenesis. In this regard, a novel dual PI3Kα/mTOR inhibitor, PI-103, has shown to be highly effective in the inhibition of both Akt and mTOR activity in vitro and in vivo (26). We therefore set out to determine whether PI-103 could provide an alternative therapeutic option for the treatment of KS. We treated EC-vGPCR cells with increasing concentrations of PI-103 and found that this drug potently inhibited the phosphorylation of Akt as well as the phosphorylation of the mTOR substrate, p70 S6K, and its downstream effector, S6 ribosomal protein (Fig. 2A).
To further explore the independent sensitivities of Akt and mTOR activation to treatment with PI-103, we coexpressed vGPCR with wild-type Rheb—the Ras-related small GTP-binding protein that promotes the activation of mTOR. Rheb is unique among members of the small GTPase family in that the regulation of its function occurs predominately through its inactivation by Rheb GTPase-activating proteins (e.g., TSC2) rather than its activation by Rheb guanine exchange factors (33); thus, overexpression of Rheb bypasses the requirement for PI3K activation of Akt to promote mTOR activity. Indeed, coexpression of Rheb was able to partially rescue the inhibition of mTOR by LY294002, but not by PI-103 (or rapamycin), confirming that PI-103 blocks S6 phosphorylation in these cells by direct inhibition of mTOR (Fig. 2B).

We next explored the effect of treating vGPCR-expressing endothelial cells with PI-103 on the phosphorylation of Akt substrates. Figure 2C shows that, unlike rapamycin, PI-103 potently inhibited the activation of GSK3, BAD, Mdm2, and p27. Collectively, these results show that PI-103, unlike LY294002 or rapamycin, is capable of inhibiting vGPCR activation of both PI3K/Akt and mTOR independently.

Simultaneous inhibition of mTOR and PI3K by PI-103 more effectively inhibits endothelial cell proliferation. We next set out to determine whether inhibition of both PI3K and mTOR would be more effective than treatment with rapamycin in preventing the proliferation of endothelial cells expressing vGPCR. To this end, we treated EC-vGPCR cells with increasing doses of PI-103, rapamycin, or LY294002. Figure 3 shows that treatment of cells with PI-103 was able to more efficiently block cell proliferation than rapamycin or LY294002 alone. The sensitivity to PI-103, as assessed by IC$_{50}$ values with ~0.2 μmol/L, achieving IC$_{80}$ values with ~8 μmol/L of compound. Furthermore, when we checked the incorporation of BrdUrd by vGPCR-expressing endothelial cells treated with the different drugs, BrdUrd uptake was more significantly reduced in PI-103–treated EC-vGPCR cells (81%) than in rapamycin-treated EC-vGPCR cells (50%; P < 0.01; Fig. 3B and C). Of note, this remarkable sensitivity of the proliferative potential of EC-vGPCR was significantly higher than that of the parental SVEC endothelial cell line (Fig. 3C), emphasizing the importance of the Akt/mTOR pathway for the proliferation of vGPCR-expressing cells. Collectively, these results suggest that, compared with rapamycin,
PI-103 is able to more effectively inhibit the proliferation of vGPCR-expressing endothelial cells.

**PI-103 promotes apoptosis in vGPCR-expressing endothelial cells.** Close examination of PI-103–treated versus rapamycin-treated EC-vGPCR cells revealed lower total cell numbers in the cells treated with the dual PI3Ka/mTOR inhibitor, suggesting that treatment with PI-103 may also more effectively promote cell death compared with rapamycin. We therefore set out to compare the efficacy of PI-103 in promoting apoptosis of endothelial cells expressing vGPCR. We cultured EC-vGPCR cells in the presence of LY294002, rapamycin, or PI-103 and analyzed the samples by flow cytometry 24 h following initiation of the treatment. Transient exposure (6 h) to PI-103 induced apoptosis in 31% of the cells compared with 20% in rapamycin-treated cells ($P < 0.05$; Fig. 4A). Prolonged treatment (24 h) with PI-103 was also associated with higher levels of apoptosis (55%) compared with rapamycin (38%; $P < 0.05$; Fig. 4B). The sensitivity of EC-vGPCR survival was higher than that of the parental SVEC endothelial cell line (results not shown), again emphasizing the importance of the Akt/mTOR pathway for vGPCR-expressing cells. These results suggest that PI-103 is able to induce apoptosis of vGPCR-expressing endothelial cells more effectively than rapamycin.

**PI-103 effectively inhibits tumor growth in an allograft model for KS.** These observations prompted us to study the therapeutic potential of PI-103 as an anti-KS treatment. We therefore established KS tumor allografts by injecting EC-vGPCR cells in athymic nu/nu mice. Once lesions were established, tumor volume was measured and then converted into tumor weight at different time points as described in Materials and Methods. When estimated tumor weight reached ~0.25 g (day 45), animals were treated with either PI-103 or vehicle (control) i.p. for 18 consecutive days (26). Tumor regression in PI-103–treated animals was observed within 2 days after the initiation of treatment, and inhibition of tumor growth was sustained for the duration of the experiment (Fig. 5A). At the end of the study (day 62), we observed that the average estimated tumor weight of vehicle-treated tumors was 1,312 mg, an ~4-fold increase in 17 days. However, the PI-103–treated group showed minimal growth over the same period, with an average estimated tumor

![Figure 4. PI-103 induces apoptosis of KSHV vGPCR-expressing cells more effectively than rapamycin. A, effect of the treatment with 10 μmol/L LY294002, 10 nmol/L rapamycin, 10 μmol/L PI-103, or DMSO (Control) on EC-vGPCR apoptosis. Cells were cultured for 6 h (A) or 24 h (B) in the presence of the different compounds. Twenty-four hours following initiation of the treatment, cells were harvested and processed for flow cytometry analysis. Results are illustrated as percentage of apoptotic cells and are from a representative independent experiment that was repeated thrice with similar results. *, $P < 0.05$.](cancerres.aacrjournals.org)
weight of 460 mg on day 62 (Fig. 5A), representing only a 1.7-fold increase in tumor mass 17 days after the initiation of the treatment with the drug. Drug toxicity, as assessed by weight loss, was minimal in the treated group (reduction <5%) during the treatment period (results not shown).

Tumors from PI-103–treated animals showed decreased cellularity (Fig. 5B). Tumor cell proliferation, as assessed by the incorporation of BrdUrd, from PI-103–treated animals was also diminished compared with control animals (Fig. 5C). In contrast, detection of apoptotic cells using TUNEL reaction showed increased cell death in PI-103–treated tumors. Immunohistochemical analysis of these tumors also showed a dramatic reduction in the levels of P-S6 compared with control animals (Fig. 5C). Of note, treatment of animals with PI-103 before establishment of tumors completely prevented tumor formation (results not shown). Taken together, our data provide the basis for the early assessment of molecules independently inhibiting the Akt and mTOR pathways, including PI-103, as an anti-KS therapy.

Discussion

The Akt/TSC/mTOR pathway, a central player in endothelial cell biology (8, 10), has been identified as a critical signaling route in vGPRC-induced Kaposi’s sarcomagenesis (9, 11, 12). We have previously shown that this viral oncogene stimulates the phosphorylation and inactivation of tuberin (TSC2), promoting the activation of mTOR and its signaling effectors (12). mTOR activation by vGPRC is necessary and sufficient for the ability of this viral oncogene to render expressing endothelial cells oncogenic (12). Moreover, mice haploinsufficient for TSC2 are predisposed to vascular sarcomas remarkably similar to KS, suggesting that the vascular tumors induced by infection with KSHV may be a consequence of the profound sensitivity of endothelial cells to dysregulation of the mTOR pathway by vGPRC (12). Indeed, infection of endothelial cells by KSHV has recently been shown to induce the activation of the PI3K/Akt/mTOR pathway, thereby promoting endothelial cell survival (34). Collectively, these data suggest that drugs targeting this important signaling route may be an effective therapeutic approach for the treatment of patients with KS.
Inhibition of PI3Kα/mTOR as a Treatment for KS

Of note, the mTOR inhibitor rapamycin (sirolimus) has recently emerged as an effective treatment for renal transplant patients with KS; the switch from other immunosuppressive agents to rapamycin leads to remission of dermal KS lesions, although effective immunosuppression is still provided (14, 35–37). More recently, classic KS has shown a similarly remarkable sensitivity to treatment with sirolimus (15, 16). This argues against a reduction in immunosuppression with this drug compared with other immunosuppressive agents and further supports a central role for the Akt/TSC/mTOR pathway in KS pathogenesis.

However, emerging evidence suggests that rapamycin may have some limitations in its clinical use as an anticancer agent. Several laboratories have shown that treatment of cancer cell lines with rapamycin results in a transient paradoxical increase in Akt phosphorylation, which seems to be due to the loss of negative feedback regulation in the PI3K/Akt pathway (21–23). This negative regulatory loop could explain the relative benign nature of tumors associated with TSC mutations and also may provide a means for tumor resistance to mTOR inhibition (21, 38).

We show here that exposure of EC-vGPCR cells to increasing doses of rapamycin leads to an increase of Akt phosphorylation, suggesting that this drug also interferes with the regulation of PI3K/Akt activity in endothelial cells expressing vGPCR. As activation of Akt alone is sufficient to promote endothelial cell transformation in vivo (11), this may prove to be an Achilles' heel for rapamycin in the treatment of KS; this may provide insight into why treatment with rapamycin has not been successful in some KS patients (17–20).

To overcome this limitation, we set out to assess the efficacy of a novel dual PI3Kα/mTOR inhibitor for the treatment of KS. Combinatorial inhibition of multiple targets has proven to be a very effective approach in the development of cancer inhibitors due to the complexity and redundancy of signaling networks underlying malignant transformation. We show here that PI-103 is able to effectively and independently block activation of both PI3K and mTOR by vGPCR in expressing endothelial cells. In turn, PI-103 inhibited the proliferation of endothelial cells expressing vGPCR in vitro and efficiently inhibited the ability of this cell line to form tumors in vivo. Inhibition of tumor growth by PI-103 correlated with the induction of apoptosis through the inhibition of the PI3K/Akt and mTOR pathways. Collectively, our results show that PI-103 may prove to be a more effective treatment for patients with iatrogenic KS.

As drugs that inhibit mTOR have been shown to exhibit potent immunosuppressive activity, this may potentially discourage its use in patients with a chronic immunosuppressive state such as occurs in AIDS-KS patients. Indeed, how mTOR inhibitors affect viral proliferation (KSHV and HIV) and the immune responses to these viruses remains unclear. However, the results of several small clinical studies suggest that immunosuppressive medications might be safe and effective for patients with stable HIV disease (39). Moreover, given the importance of immune activation for HIV disease progression, it has been suggested that pharmacologic modulation of immune activation may be of potential benefit in slowing down the rate of AIDS progression (39). In addition, it has been shown that rapamycin may exert a direct antiretroviral effect by repressing HIV replication (40). The administration of rapamycin to nonhuman primates has also been shown to decrease CCR5 mRNA expression in vivo, further suggesting that rapamycin treatment may promote the prevention and treatment of HIV infection (41). Of note, it has also been hypothesized that coreceptor activation of the PI3K/Akt signaling pathway by HIV gp120 may promote the survival of infected T lymphocytes in HIV patients (4). In light of our results, this suggests that simultaneous inhibition of both mTOR and PI3K, as occurs with PI-103, may provide an effective therapeutic approach for patients with AIDS-KS.

Our results may have more broad implications. Emerging appreciation for rapamycin as an antiangiogenic treatment suggests that drugs targeting the mTOR pathway may prove to be an effective antiangiogenic strategy for the treatment of a variety of diseases. Indeed, as KS may serve as a model for tumor-induced or pathologic angiogenesis, our results collectively provide the basis for the early assessment of PI-103 as an anti-KS and antiangiogenic chemotherapeutic agent.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 3/21/2008; revised 7/28/2008; accepted 8/6/2008.

Grant support: National Cancer Institute, NIH grant RO1CA119911. B.C. Jham is a recipient of a predoctoral fellowship from the CNPq-Brazil.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Histoserv, Inc. for their assistance in the processing of the murine tissues.

References


